Discover the latest trends in downstream bioprocessing from industry leaders from BioProcess International and 3M.
Within downstream bioprocessing, there are mounting challenges and bottlenecks from pipelines with increasingly diverse and complicated modalities. At the same time there are several areas of exciting development with the potential to revolutionize the field.
Here we explore some recent trends in bioprocessing that expand the toolbox available to downstream scientists and engineers. It features insights from key industry leaders who
provide solutions (utilising novel tools, technologies and strategies), through their own recent experiences.
The experts include Prof. Alois Jungbauer from BOKU, Prof. Dan Bracewell from UCL, and Dr. Hani El-Sabbahy from 3M Company, who gathered to discuss the topics for a webinar I hosted at the BioProcess International Europe Digital Week 2021 in partnership with 3M Company.
The trends fall under two overarching topics:
Dr. Hani El-Sabbahy, 3M Company
Dr. Hani El-Sabbahy is an Advanced Application Engineering Specialist, based in the UK, focusing on biopharmaceutical purification. Using 3M purification technologies, he is responsible for replicating existing applications, developing new applications, and deploying new technologies at global biopharmaceutical manufacturers. Hani has also established and led a number of research collaborations. Prior to joining 3M, he worked as a Senior Downstream Process Development Scientist at Actavis Biologics where he developed expertise in continuous downstream processing. He has 15 years of experience in downstream process development for biopharmaceuticals and obtained his PhD in Biochemical Engineering from UCL.
Prof. Daniel G. Bracewell, UCL
Daniel G. Bracewell is Professor of Bioprocess Analysis at the UCL Department of Biochemical Engineering. He has made major contributions to the fundamental understanding of biopharmaceutical purification operations, including collaborations with Thailand, India and the USA. He has authored more than 90 peer reviewed journal articles in the area to date and currently supervises 15 doctoral and postdoctoral projects, many of these studies are in collaboration with industry. One such project was the basis from which the spinout Puridify (recently acquired by GE Healthcare) was created.
Prof. Alois Jungbauer, BOKU
Professor Alois Jungbauer received his PhD in Food Technology and Biotechnology from BOKU. He serves as a professor at the Department of Biotechnology at BOKU. He teaches Protein Technology and Downstream Processing and Bioprocess Engineering and is study director of the Ph.D. program Bioprocess Engineering. He also acts as area head of Bioprocessing Engineering and Deputy Director of Research in the Austrian Centre of Industrial Biotechnology.
